Effect Of Kasmaryadi Kashaya In The Management of Elevated Serum Uric acid level.

A Clinical Trial to Evaluate The Efficacy Of Kasmaryadi Kwatha In The Management Of Hyperuricemia. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069896

Enrollment

Registered

2024-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Subjects in the age group between 18-60 years having elevated Serum uric acid level above 6.8 mg/dL. 2) Subjects irrespective of gender and socio-economic status. 3) Subjects who are willing to sign the consent form.

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women. 2) Subjects with known cases of Malignancy, Diabetes mellitus, any Concurrent Hepatic disorders, Chronic Renal failure, Hyperthyroidism and Hypothyroidism 3) Subjects on medication with aspirin (low dose 1-2 g per day), beta blockers and alpha -1 blockers for hypertension, antidepressants, modern diuretics and on medication of hyperuricemia. 4) Known alcoholic subjects and subjects consuming high purine diet.

Design outcomes

Primary

Measure	Time frame
1.To study the efficacy of Kasmaryadi Kwatha in the management of Hyperuricemia 2.To assess the efficacy of Kasmaryadi Kwatha in reducing symptoms of symptomatic patients using Brief Pain Inventory Scale and in improving quality of life assessed by Bengali version of Questionnaire assessing impact of hyperuricemia on quality of lifeTimepoint: 1.Serum Uric acid test. 2.Pain (Assessed by brief pain inventory scale) 3.Quality of life (Assessed by Bengali version of questionnaire assessing impact of hyperuricemia on quality of life). Assessment will be done on 0th day, 8th day, 16th day and 31st day	—

Measure

Time frame

1.To study the efficacy of Kasmaryadi Kwatha in the management of Hyperuricemia 2.To assess the efficacy of Kasmaryadi Kwatha in reducing symptoms of symptomatic patients using Brief Pain Inventory Scale and in improving quality of life assessed by Bengali version of Questionnaire assessing impact of hyperuricemia on quality of lifeTimepoint: 1.Serum Uric acid test. 2.Pain (Assessed by brief pain inventory scale) 3.Quality of life (Assessed by Bengali version of questionnaire assessing impact of hyperuricemia on quality of life). Assessment will be done on 0th day, 8th day, 16th day and 31st day

—

Secondary

Measure	Time frame
To assess the safety of Kasmaryadi Kwatha in subjects diagnosed with Hyperuricemia. Timepoint: Liver Function Test,Renal Function Test,Random Blood Sugar and Blood Routine Examination with ESR will be done on 0th and 16th day to assess safety	—

Countries

India

Contacts

Public ContactThushara R

Pankajakasthuri Ayurveda Medical College and PG Centre Kattakada

rthushara88@gmail.com9446876734

Outcome results